P3 Health Partners Inc. Post-effective amendment to a registration statement that is not immediately effective upon filing

Post-effective amendment to a registration statement that is not immediately effective upon filing

Net Loss per Share (Tables)

Net Loss per Share (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table provides the computation of basic and diluted net loss per share:


		Three Months Ended March 31,
		2023			2022

		(in thousands, except per share data)
Net loss attributable to Class A common stockholders–basic and diluted		$	(9,199)		$	(10,577)
Weighted average Class A common shares outstanding–basic and diluted			41,579			41,579
Net loss per share attributable to Class A common stockholders–basic and diluted		$	(0.22)		$	(0.25)


		Year Ended			December 3, 2021
		December 31,			through December 31,
		2022			2021
Net loss attributable to Class A common stockholders-basic and diluted		$	(270,127)		$	(10,081)

Weighted average Class A common shares outstanding-basic and diluted			41,579			41,579

Loss per share attributable to Class A common stockholders-basic and diluted		$	(6.50)		$	(0.24)

Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Net Loss Per Share


		Three Months Ended March 31,
		2023		2022

		(in thousands)
Stock warrants ⁽¹⁾		11,248		10,819
Stock options ⁽¹⁾		5,487		2,134
Shares of Class V common stock ⁽²⁾		201,972		202,025
Total		218,707		214,978

(1)	Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share.

(2)	Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under the application of the if-converted method.


		Year Ended			December 3, 2021
		December 31,			through December 31,
		2022			2021
Stock warrants⁽¹⁾			11,248			10,819
Stock options⁽¹⁾			3,402			—
Shares of Class V common stock⁽²⁾			201,972			202,025
Total			216,622			212,844

(1)	Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share

(2)	Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under application of the if-converted method.